NCT05454020View on ClinicalTrials.gov

A Study of Topical XG004 in Participants With Osteoarthritis of the Knee

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

January 23, 2023

Study Completion Date

March 21, 2023

Conditions
Pain
Interventions
DRUG

XG004

XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.

DRUG

Placebo

Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.

Trial Locations (1)

5000

PARC Clinical research, Adelaide

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Xgene Pharmaceutical Group

INDUSTRY